Karyopharm: EC Grants Addl. Orphan Designation For Selinexor - Quick Facts

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, said its lead drug candidate, Selinexor (KPT-330), has received orphan drug designation from the European Medicines Agency or EMA of the European Commission to treat chronic lymphocytic leukemia or CLL and small lymphocytic lymphoma or SLL, including Richter's Transformation, and multiple myeloma.

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound. It has previously received orphan designation in acute myeloid leukemia or AML and diffuse large B-cell lymphoma or DLBLC from both the EMA and the U.S. Food and Drug Administration or FDA.

"The granting of orphan designation by the EMA for these hematologic malignancies represents a further significant achievement for our Selinexor development program," commented Sharon Shacham, President and Chief Scientific Officer of Karyopharm. He added, "There continues to be limited treatment options for patients with these serious blood cancers, particularly for those patients who fail to achieve and maintain responses on available therapies. We are excited about the prospects for oral Selinexor's novel mechanism of action to potentially treat these challenging conditions, either alone or in combination with other therapies."